SCHEMBL512106

SCHEMBL512106

O=C1CCCC1c1ccc(Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A1 P18405 1/20 0.41
HTR3A P46098 1/20 0.40
GABRA1 P14867 1/20 0.40
GABRA5 P31644 1/20 0.40
LIG1 P18858 1/20 0.40
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
KDM4E B2RXH2 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
ALDH1A1 P00352 1/20 0.37
SLC2A1 P11166 1/20 0.37
RAB9A P51151 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1616775 0.94 KDM4E (0.42) SRD5A1HTR3ALIG1KDM4ESMN1; SMN2
SCHEMBL15874655 0.94 KDM4E (0.42) SRD5A1HTR3ALIG1KDM4ESMN1; SMN2
SCHEMBL11840693 0.92 KMT2A (0.42) SRD5A1HTR3ALIG1KDM4ESMN1; SMN2
SCHEMBL11837854 0.88 CA1 (0.41) SRD5A1GABRA1GABRA5KDM4ESMN1; SMN2
SCHEMBL15282087 0.88 SRD5A1 (0.43) SRD5A1HTR3ALIG1HSD17B10KDM4E
SCHEMBL361341 0.80 LMNA (0.43) LIG1ALOX15TSHRALDH1A1SLC6A2
SCHEMBL4917555 0.80 LIG1 (0.40) LIG1ALOX15TSHRMEN1KMT2A
SCHEMBL361599 0.79 DDB1 (0.48) ALOX15TSHRKMT2AMAPT
SCHEMBL23468094 0.77 TRIM24 (0.36) HSD17B10KDM4ESMN1; SMN2ALDH1A1
SCHEMBL11818914 0.77 GAA (0.41) SRD5A1HTR3ALIG1TSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111662262-B Synthesis method of 6- (4- ((2-cyclohexylthio ethyl) amino) phenyl) tetrahydro-2H-pyran-2-one 陕西大美化工科技有限公司 2023-04-28 CN claimed
CN-111662262-A Synthesis method of 6- (4- ((2-cyclohexylthio ethyl) amino) phenyl) tetrahydro-2H-pyran-2-one 怀宁大有医药科技有限公司 2020-09-15 CN claimed
CN-111662262-B Synthesis method of 6- (4- ((2-cyclohexylthio ethyl) amino) phenyl) tetrahydro-2H-pyran-2-one 陕西大美化工科技有限公司 2023-04-28 CN disclosed
CN-111662262-A Synthesis method of 6- (4- ((2-cyclohexylthio ethyl) amino) phenyl) tetrahydro-2H-pyran-2-one 怀宁大有医药科技有限公司 2020-09-15 CN disclosed
EP-2668168-B1 COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION BRISTOL MYERS SQUIBB CO (US) 2017-03-01 EP disclosed
EP-2668168-B1 COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION BRISTOL MYERS SQUIBB CO (US) 2017-03-01 EP disclosed
US-20150336975-A1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2015-11-26 US disclosed
US-20150336975-A1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2015-11-26 US disclosed
US-20150336975-A1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2015-11-26 US disclosed
EP-2459197-B1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL MYERS SQUIBB CO (US) 2015-10-14 EP disclosed
EP-2459197-B1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL MYERS SQUIBB CO (US) 2015-10-14 EP disclosed
US-20110212937-A1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL-MYERS SQUIBB COMPANY 2011-09-01 US disclosed
WO-2011014535-A1 COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2011-02-03 WO disclosed
WO-2011014535-A1 COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2011-02-03 WO disclosed
US-4153235-A HYPOGLYCEMIC, HYPOTENSIVE, ANTIINFLAMMATORY, ANTICOAGULANT, DIURETIC ACTIVITIES RICHARDSON-MERRELL INC. (US) 1979-05-08 US disclosed
US-4126613-A HYPOGLYCEMIC, HYPOTENSIVE, ANTIINFLAMMATORY, ANTICOAGULANT, DIURETIC RICHARDSON-MERRELL INC. (US) 1978-11-21 US disclosed
US-4126621-A HYPOGLYCEMIC, HYPOTENSIVE, ANTIINFLAMMATORY, ANTICOAGULANT, DIURETIC RICHARDSON-MERRELL INC. (US) 1978-11-21 US disclosed
US-4126612-A HYPOGLYCEMIC, HYPOTENSIVE, ANTIINFLAMMATORY, ANTICOAGULANT, DIURETIC Retter, Eugene O. (US) 1978-11-21 US disclosed
US-4126611-A HYPOGLYCEMIC, HYPOTENSIVE, ANTIINFLAMMATORY, ANTICOAGULANT, DIURETIC RICHARDSON-MERRELL INC. (US) 1978-11-21 US disclosed
US-4061746-A Lactamimide inhibitors of gastrointestinal hypersecretion RICHARDSON-MERRELL INC. (US) 1977-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212937-A1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION APP, BACE1, IAPP SRD5A1 2535/4885HTR3A 3093/4885GABRA1 1861/4885
US-20150336975-A1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION APP, BACE1, IAPP SRD5A1 2535/4885HTR3A 3093/4885GABRA1 1861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.